Now let me write the final consolidated review.

## Summary

This paper introduces PPI candidate ranking — a prospective task that prioritizes novel protein-protein interactions for experimental validation — and proposes a two-stage framework combining interpretability-guided retrieval (using active embedding regions from predicted contact maps of D-SCRIPT/Topsy-Turvy) with multi-source re-ranking (interaction scores, structural plausibility via pDockQ, functional annotation overlap, and biomedical LLM-based semantic signals). Evaluation on STRING v11→v12 transitions, where known interactions from v11 seed the ranking and novel v12 interactions serve as ground truth, shows that the method substantially improves early ranking metrics over baseline prediction probabilities.

## Strengths

1. **Prospective evaluation paradigm is a genuine methodological contribution.** The paper defines PPI candidate ranking as a distinct task and validates it using successive STRING releases (v11→v12), which is a more realistic assessment of predictive value than static retrospective benchmarks. This is clearly articulated in Section 1: "Existing PPI benchmarks are largely static and retrospective... do not assess whether computational methods can anticipate interactions that will only be experimentally confirmed in future updates."

2. **Interpretability-guided retrieval yields large and practically meaningful improvements.** Using active embedding regions from predicted contact maps raises D-SCRIPT Recall@10 from 0.0124 to 0.2641 (~21x) and MRR from 0.0340 to 0.1685 (~5x) in Table 1. The method also outperforms the more recent xCAPT5 at most cutoffs (e.g., MAP@5: 0.2714 vs. 0.1481, Recall@10: 0.2641 vs. 0.0747). These gains mean that ~13% of the top-10 candidates are genuine novel partners — a practically useful hit rate for screening.

3. **Systematic multi-source re-ranking analysis reveals complementary signals.** Table 2 provides a pairwise rank-shift analysis across 10 evidence sources (cosine, interaction score, pDockQ, TF-IDF, Token/Location/KeyTerm overlap, BioBERT, BioMedRoBERTa, PubMedBERT). The finding that PubMedBERT improves or maintains 75.5% of rediscoveries over cosine, while lightweight heuristics like KeyTerm overlap achieve 69.3%, directly informs practitioners about which signals to prioritize.

4. **Large-scale, carefully filtered dataset.** The pipeline processes 279,568 additional v12 interactions with stringent filtering (experimental support >0, 50–800 residue length, CD-HIT 40% redundancy reduction, 10:1 negative ratio), providing a robust testbed.

5. **Clear discussion of limitations.** Section 6 honestly acknowledges the reliance on known partners (limiting applicability for underexplored proteins) and the fact that the embedding representations remain non-interpretable in a biologically meaningful sense.

## Weaknesses

### Fatal
None.

### Major

None.

### Minor

1. **The "two orders of magnitude" claim is overstated.** The abstract (line 9), introduction (line 25), and conclusion (line 279) state that the method "improves ranking metrics by two orders of magnitude." However, the largest improvement in Table 1 is Recall@10 (0.0124→0.2641 ≈ 21x, one order of magnitude) and Success@10 (0.0040→0.1277 ≈ 32x). MRR improves ~5x. The actual gains are impressive enough that this exaggeration is unnecessary and undermines precision. The authors should recalibrate this to match the reported numbers (e.g., "up to an order of magnitude" or state specific metric ratios).

2. **PubMedBERT cross-encoder comparison is asymmetric.** In Table 2, PubMedBERT (75.5% maintain/improve over cosine) is compared against off-the-shelf bi-encoders BioBERT (55.8%) and BioMedRoBERTa (56.1%). However, PubMedBERT receives task-specific fine-tuning on STRING v11 interaction labels (Section 4.2, lines 143-148), while the bi-encoders are used without any fine-tuning. The paper mentions uncertainty about whether the gains reflect "latent knowledge of interactions from the training data" but does not explicitly acknowledge that the advantage is partly attributable to task-specific supervision rather than superior model architecture. A fairer comparison would either fine-tune all models or evaluate PubMedBERT without fine-tuning.

3. **xCAPT5 baseline comparison lacks sufficient contextualization.** xCAPT5 is included in Table 1 with substantially lower prediction coverage (0.8088 vs. 0.9544 for D-SCRIPT and 0.9683 for Topsy-Turvy) and worse average rank (900.11 vs. 482.86 and 570.52). The paper states xCAPT5 "rapidly decays as k increases" — which is directionally true (Precision@5=0.1943→Precision@10=0.1848→Precision@50=0.1427) — but xCAPT5's early precision is the best of any probability baseline. The paper should explicitly discuss the coverage disparity and why a method with strong early precision has a worse average rank, since this affects interpretability of the comparison.

4. **Re-ranking analysis lacks statistical significance and operates on limited scope.** The pairwise rank-shift analysis in Table 2 covers only the top-10 candidates per protein (2,280 pairs), and no confidence intervals or significance tests are reported. The observed differences (e.g., PubMedBERT 75.5% vs. BioBERT 55.8%) could be driven by a small number of outlier proteins. The top-10 restriction is reasonable given computational constraints (acknowledged in Section 4.2), but the conclusions about relative re-ranker quality would be stronger with per-protein variance or bootstrap confidence intervals.

### Trivial

1. **Table 2 caption references symbols (†, ‡) that do not appear in the table body.** The caption mentions "† reports the fraction... and ‡ is reported" but these symbols are absent from the printed table.

## Nice-to-Haves

- **Ablation isolating interpretability component**: Comparing against retrieval using full embeddings (without restriction to active residues) would isolate whether the contact-map-based residue selection drives the improvement, or whether the embedding structure alone suffices. This would strengthen the central claim.
- **Success/failure case studies**: Concrete examples of proteins where the method works well and where it fails would ground the limitations discussion and provide scientific insight.
- **Provide code and processed data**: If not already present in the appendix (stripped by the parser), releasing the processed STRING v11/v12 data and code would benefit reproducibility.

## Removed Points

These points were raised in the inputs but are removed; treat with caution.

- **"No code or data availability statement"** — REMOVED: The appendix and references are stripped by the parser; such statements may exist in the original submission.
- **"Statistical significance is absent" as a major weakness** — WEAKENED to Minor (point 4 above). The large-scale evaluation provides credible evidence; the issue mainly affects the re-ranking analysis.
- **"Contiguous segment assumption may not hold for discontinuous epitopes"** — MOVED to Nice-to-Have: This is a reasonable methodological design choice, not a flaw.
- **"Missing related works"** — REMOVED: Per meta-review instructions, I cannot verify the existence of missing citations.
- **Formatting nitpicks (typos, broken characters)** — REMOVED: These are parser artifacts, not author errors.
- **"The re-ranking maintain-or-improve framing conflates different scenarios"** — REMOVED: This is a standard evaluation approach for re-ranking tasks.
- **"The paper lacks a clear summary of limitations"** — REMOVED: Section 6 explicitly discusses limitations.
- **Weaknesses from Strength Finder about generic strengths** — REMOVED: The remaining strengths are concrete and evidence-backed.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. Recalibrate the "two orders of magnitude" claim to match the actual improvements (e.g., "up to an order of magnitude" or precise metric ratios).
2. Add a fairer comparison for PubMedBERT vs. bi-encoders — either fine-tune all models equally or evaluate without fine-tuning.
3. Provide confidence intervals or per-protein variance estimates for the re-ranking analysis in Table 2.
4. Add an ablation comparing active-region-based retrieval against full-embedding retrieval to isolate the benefit of the contact-map selection.
5. Discuss the xCAPT5 coverage disparity explicitly in the main text to contextualize the comparison.

## Score and Decision

### Calibration Anchors

**Round 1 (Bracketing)**

| Paper | Path | Avg Score | Round | Comparison |
|---|---|---|---|---|
| Advancing Drug-Target Interaction Prediction via Graph Transformers | S2WHlhvFGg.md | 3.00 | R1 | Much weaker — unclear claims, no empirical validation of theory |
| Comparing Protein Language Models Using Remote Homology Detection | IEZjjDX0iC.md | 3.00 | R1 | Weaker — narrow scope, limited evaluation |
| LLM and Protein Assistant for PPI prediction (LLaPA) | eh1fL0zw8o.md | 6.00 | R1 | Comparable — similar domain, but our paper has cleaner evaluation and fewer methodological concerns |
| MAPE-PPI | itGkF993gz.md | 5.67 | R1 | Comparable — both PPI papers, but our problem formulation is more novel |
| MARS: Neurosymbolic for drug discovery | STBPaproaB.md | 5.50 | R1 | Comparable — different domain, similar level of contribution |
| GeSubNet | ja4rpheN2n.md | 8.00 | R1 | Stronger — more polished, stronger claims, but different domain |
| Protein Discovery with Discrete Walk-Jump Sampling | zMPHKOmQNb.md | 8.00 | R1 | Stronger — rigorous theory, clean results |
| ProtComposer | 0ctvBgKFgc.md | 8.00 | R1 | Stronger — novel generative framework |

**Round 2 (Narrowing)**

| Paper | Path | Avg Score | Round | Comparison |
|---|---|---|---|---|
| LLaPA | eh1fL0zw8o.md | 6.00 | R2 | Comparable — our paper has a cleaner evaluation and more novel problem |
| PEEP | 760br3YEtY.md | 5.60 | R2 | Slightly weaker — more incremental methodology |
| ReNovo | uQnvYP7yX9.md | 6.50 | R2 | Comparable — both introduce new tasks with strong empirical validation |
| MAPE-PPI | itGkF993gz.md | 5.67 | R2 | Comparable — our problem formulation is more novel |
| Illuminating Protein Function (ProtIR) | jsQPjIaNNh.md | 5.25 | R2 | Weaker — less clean evaluation, many methodological concerns |
| BioBridge | jJCeMiwHdH.md | 7.00 | R2 | Slightly stronger — more polished, but different domain |
| SEPIT | 8CKgS18uWx.md | 6.25 | R2 | Comparable — similar tier of contribution |
| Redefining Bioactivity Prediction | S8gbnkCgxZ.md | 7.00 | R2 | Slightly stronger — sharper claims, cleaner evaluation |

**Round-1 bracket**: (4.5, 7.5)
**Round-2 narrowing**: The paper sits between 5.6 (PEEP) and 6.5 (ReNovo), comparable to LLaPA (6.0) and SEPIT (6.25). The paper introduces a genuinely novel problem (PPI candidate ranking with prospective evaluation), which is a stronger contribution than the incremental methodology in PEEP and ProtIR. The evaluation is large-scale and well-designed. However, the overclaimed "two orders of magnitude" and the asymmetric PubMedBERT comparison prevent this from reaching the 6.5–7.0 tier of cleaner, better-calibrated papers. The paper is solidly above the 5.25–5.67 papers (ProtIR, MAPE-PPI, PEEP) but below the 7.0 papers (BioBridge, Redefining Bioactivity).

**Final score: 6.0**

**Rationale**: The paper's core contributions — the prospective evaluation paradigm for PPI candidate ranking and the interpretability-guided retrieval mechanism — are novel and practically significant. The empirical evidence is substantial and credible. However, the overstated claims and the asymmetric model comparison are real weaknesses that prevent a higher score. At 6.0, this paper is a solid acceptance for its contributions, comparable to ReNovo (6.50) and above MAPE-PPI (5.67), with issues that are addressable in revision.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>